Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 5/20 | 0.51 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.46 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19393417 | 0.89 | KIF11 (0.52) | SLC6A1KIF11 | |
| SCHEMBL16472613 | 0.85 | SLC6A11 (0.47) | SLC6A11SLC6A1TP53MEN1CYP1A2 | |
| SCHEMBL14866488 | 0.84 | SLC6A11 (0.47) | SLC6A11SLC6A1TP53MEN1CYP1A2 | |
| SCHEMBL28628138 | 0.84 | SLC6A11 (0.47) | SLC6A11SLC6A1TP53MEN1CYP1A2 | |
| SCHEMBL30861823 | 0.82 | SLC6A11 (0.53) | SLC6A11SLC6A1TP53MEN1CYP1A2 | |
| SCHEMBL23777354 | 0.82 | TP53 (0.47) | SLC6A11SLC6A1TP53MEN1CYP1A2 | |
| SCHEMBL6839724 | 0.82 | SLC6A11 (0.50) | SLC6A11SLC6A1TP53MEN1CYP1A2 | |
| SCHEMBL13020551 | 0.81 | SLC6A11 (0.43) | SLC6A11SLC6A1TP53MEN1CYP1A2 | |
| SCHEMBL13575117 | 0.81 | SLC6A11 (0.45) | SLC6A11SLC6A1TP53MEN1CYP1A2 | |
| SCHEMBL31003057 | 0.81 | SLC6A11 (0.45) | SLC6A11SLC6A1TP53MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9211343-B2 | siRNA conjugate and preparation method thereof | BIONEER CORPORATION (KR) | 2015-12-15 | — | — | US | disclosed |
| US-20140350233-A1 | SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | BIONEER CORPORATION (KR) | 2014-11-27 | — | — | US | disclosed |
| US-20140350232-A1 | SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | BIONEER CORPORATION (KR) | 2014-11-27 | — | — | US | disclosed |
| US-8779114-B2 | siRNA conjugate and preparation method thereof | BIONEER CORPORATION (KR) | 2014-07-15 | — | — | US | disclosed |
| US-8772472-B2 | SiRNA conjugate and preparation method thereof | BIONEER CORPORATION (KR) | 2014-07-08 | — | — | US | disclosed |
| US-20130096288-A1 | siRNA conjugate and preparation method thereof | BIONEER CORPORATION (KR) | 2013-04-18 | — | — | US | disclosed |
| US-20120108803-A1 | SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | BIONEER CORPORATION (KR) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350233-A1 | SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | PHAX, RNASE1, MCTS1 | SLC6A11 4189/4885SLC6A1 3925/4885TP53 883/4885 |
| US-20120108803-A1 | SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | PHAX, RNASE1, MCTS1 | SLC6A11 4189/4885SLC6A1 3925/4885TP53 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.